Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 58, Issue -, Pages 1-15Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2021.02.002
Keywords
COVID-19; SARS-CoV-2; Neuroinflammation; Integrins; Neurological disorders; Fibrosis
Categories
Funding
- National Institutes of Health [R01 NS065842, R01 NS089515]
- National Institutes of Health/NIMH [K01 MH117343]
Ask authors/readers for more resources
SARS-CoV-2 is a novel coronavirus that causes the COVID-19 pandemic and severely affects the respiratory system, impacting the central nervous system as well. Older individuals with underlying neurological conditions such as stroke, Alzheimer's disease, and Parkinson's disease are more likely to experience complications associated with COVID-19.
SARS-CoV-2 is a novel coronavirus that severely affects the respiratory system, is the cause of the COVID-19 pandemic, and is projected to result in the deaths of 2 million people worldwide. Recent reports suggest that SARS-CoV-2 also affects the central nervous system along with other organs. COVID-19-associated complications are observed in older people with underlying neurological conditions like stroke, Alzheimer?s disease, and Parkinson?s disease. Hence, we discuss SARS-CoV-2 viral replication and its inflammation-mediated infection. This review also focuses on COVID-19 associated neurological complications in individuals with those complications as well as other groups of people. Finally, we also briefly discuss the current therapies available to treat patients, as well as ongoing available treatments and vaccines for effective cures with a special focus on the therapeutic potential of a small 5 amino acid peptide (PHSCN), ATN-161, that inhibits SARS-CoV-2 spike protein binding to both integrin ?5131 and ?5131/hACE2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available